Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedtrastuzumab deruxtecan
Educational only, not medical advice. OncoForge makes no claim that Trastuzumab Deruxtecan treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
This retrospective single-center study identified 10 patients with HER2-expressing (IHC 2+/3+) recurrent or metastatic gynecological cancers who received trastuzumab deruxtecan (5.4 mg/kg IV every 3 weeks). The cohort had a median progression-free survival of 5.4 months (95% CI 0.8-9.8). Five patients had a partial response, one had stable disease at 12 weeks, and four had disease progression at initial assessment. Clinical benefit was observed mainly in tumors with HER2 IHC 3+.
Reported effects: median PFS 5.4 mo [0.8–9.8], n=10 · partial responses 5, n=10 · +2 more
Key findings
10 patients with recurrent/metastatic HER2-expressing gynecological malignancies were treated with T-DXd.
Histologies included uterine neoplasms (n=5), cervical squamous carcinoma (n=1) and ovarian cancers (n=4).
Median age was 65.4 years (25th-75th percentile, 58.1-75.2 years).
HER2 by IHC: 5 patients were 3+ and 5 patients were 2+.
Median number of prior therapy lines was 4 (range 2-6); 2 uterine serous carcinoma patients were pretreated with trastuzumab and 4 patients had prior immunotherapy.
Dose: T-DXd 5.4 mg/kg IV every 3 weeks until progression/toxicity.
Median progression-free survival (PFS) in the cohort was 5.4 months (95% CI 0.8-9.8 months).
Responses: 5 patients had partial response (including 2 previously treated with trastuzumab), 1 patient had stable disease at 12 weeks, 4 patients had disease progression at initial assessment.
Most patients who derived clinical benefit had HER2 IHC 3+ expression.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract; Potential selection and reporting bias inherent to retrospective series.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveModerate evidenceTier 4 · clinicaln = 32
This phase II study tested trastuzumab deruxtecan in people with recurrent uterine carcinosarcoma whose tumors expressed HER2. The study found tumor responses in both the HER2-high and HER2-low groups, and the median progression-free survival and overall survival were reported for each group. Side effects were common, including some serious adverse events and pneumonitis/interstitial lung disease, but the authors said they were generally manageable with monitoring.
Reported effects: ORR by central review 54.5% [32.2–75.6], n=22 · ORR by central review 70% [34.8–93.3], n=10 · +6 more
Key findings
Central-review ORR was 54.5% in the HER2-high group and 70.0% in the HER2-low group.
Investigator-assessed ORR was 68.2% in the HER2-high group and 60.0% in the HER2-low group.
Median PFS was 6.2 months in the HER2-high group and 6.7 months in the HER2-low group.
Median OS was 13.3 months in the HER2-high group and not reached in the HER2-low group.
Grade ≥3 adverse events occurred in 61% of patients.
Pneumonitis/interstitial lung disease occurred in 24% at grade 1-2 and 3% at grade 3.
Limitations: Single-arm study with no control group; Small sample size; Short/unclear follow-up for survival outcomes; Subgroup analyses were exploratory; Safety and efficacy were assessed in a selected HER2-expressing recurrent population.
This study evaluated an anticancer agent in patients with HER2-expressing uterine carcinosarcoma.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Trastuzumab Deruxtecan's evidence base, and anything that's been retracted.
Cancers where Trastuzumab Deruxtecan reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Limitations: Retrospective, single-center design; Very small sample size (n=10); No control or comparator arm; Heterogeneous mix of gynecologic histologies; Heavily pre-treated population limits generalizability; Limited/absent reporting of safety or adverse event data in the abstract.
Evidence at a glance: Trastuzumab Deruxtecan by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
These are doses as studied or reported, never a recommendation. The right amount of Trastuzumab Deruxtecan depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
3 ongoing · 0 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.